Juan F. Martínez-Lage

ORCID: 0000-0003-2562-3450
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cerebrospinal fluid and hydrocephalus
  • Head and Neck Surgical Oncology
  • Fetal and Pediatric Neurological Disorders
  • Spinal Dysraphism and Malformations
  • Craniofacial Disorders and Treatments
  • Neurosurgical Procedures and Complications
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Glioma Diagnosis and Treatment
  • Meningioma and schwannoma management
  • Cleft Lip and Palate Research
  • Vascular Malformations Diagnosis and Treatment
  • Spine and Intervertebral Disc Pathology
  • Neurofibromatosis and Schwannoma Cases
  • Child Abuse and Related Trauma
  • Spinal Hematomas and Complications
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Spinal Fractures and Fixation Techniques
  • Intracranial Aneurysms: Treatment and Complications
  • Infectious Diseases and Tuberculosis
  • Teratomas and Epidermoid Cysts
  • Neonatal Respiratory Health Research
  • Facial Trauma and Fracture Management
  • Musculoskeletal pain and rehabilitation
  • Bacterial Infections and Vaccines
  • Prion Diseases and Protein Misfolding

Hospital Universitario Virgen de la Arrixaca
2008-2020

Universidad de Murcia
2005-2017

Boston Children's Hospital
2005-2012

Instituto de Neurologia Y Neurocirugia
2001-2011

Servicio Murciano de Salud
2003-2011

Centro Médico Sanitas Murcia
1999-2008

National Institute of Infectious Diseases
2000

National Health Service
1991-1997

Western General Hospital
1994

National Institute of Neurological Disorders and Stroke
1994

Abstract The objective of this article is to assess the safety intraspinal infusion autologous bone marrow mononuclear cells (BMNCs) and, ultimately, look for histopathological signs cellular neurotrophism in amyotrophic lateral sclerosis (ALS) patients. We conducted an open single arm phase I trial. After 6 months observation, BMNCs were infused into posterior spinal cord funiculus. Safety was primary endpoint and defined as absence serious transplant-related adverse events. In addition,...

10.1002/stem.1080 article EN Stem Cells 2012-03-13

We tested DNA from 15 centrally infected cases of iatrogenic Creutzfeldt-Jakob disease (CJD) (dura mater or corneal homografts and stereotactic EEG electrodes), 11 peripherally (native human growth hormone gonadotrophin), 110 control individuals for the presence mutations in chromosome 20 amyloid gene. No patient had any known pathogenic point insert found familial disease, but allelic homozygosity at polymorphic codon 129 was present all two (92%) 26 patients, compared with 54 (50%)...

10.1212/wnl.44.2.291 article EN Neurology 1994-02-01

Four patients who received dural grafts of cadaveric origin in the course posterior fossa procedures subsequently developed Creutzfeldt-Jakob disease (CJD). The interval from placement to clinical onset CJD ranged 16 months nine years. Initial presentation consisted cerebellar symptoms, with dementia and myoclonus developing later stages disease. EEGs showed diffuse slowing that evolved a periodic activity pattern. CT MRI were unremarkable early but pronounced cerebral atrophy widened sulci...

10.1136/jnnp.57.9.1091 article EN Journal of Neurology Neurosurgery & Psychiatry 1994-09-01

The occurrence of bilateral temporal arachnoid cysts has been considered as a rare event. Unilateral pouches have reported in few instances associated with neurofibromatosis. authors describe 5-year-old girl who presented obvious stigmata von Recklinghausen's disease. To the best our knowledge, this is first time that association described literature. (J Child Neurol 1993;8:383-385).

10.1177/088307389300800417 article EN Journal of Child Neurology 1993-10-01

Object The aim of this study was to evaluate whether clinical improvement is noticeable after a minimally invasive procedure such as that used with the Aperius PercLID System in patients degenerative lumbar spinal stenosis (DLSS) and neurogenic intermittent claudication (NIC). Methods were treated aforementioned system at 3 different centers. initial requirement be included minimum follow-up 12 months. authors studied 40 cases DLSS NIC (age 72.7 ± 8.08 years). Symptom severity, physical...

10.3171/2010.3.focus1034 article EN Neurosurgical FOCUS 2010-06-01
Coming Soon ...